

## Unlocking acid ceramidase: a new weapon against proteasome chemoresistance in myeloma

by Jesus Delgado-Calle

Received: December 3, 2024.

Accepted: December 17, 2024.

Citation: Jesus Delgado-Calle. Unlocking acid ceramidase: a new weapon against proteasome chemoresistance in myeloma.

Haematologica. 2025 Jan 2. doi: 10.3324/haematol.2024.286925 [Epub ahead of print]

### *Publisher's Disclaimer.*

*E-publishing ahead of print is increasingly important for the rapid dissemination of science.*

*Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication.*

*E-publishing of this PDF file has been approved by the authors.*

*After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in a regular issue of the journal.*

*All legal disclaimers that apply to the journal also pertain to this production process.*

# **Unlocking acid ceramidase: a new weapon against proteasome chemoresistance in myeloma**

Jesus Delgado-Calle<sup>1,2,3,4\*</sup>

<sup>1</sup>Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, AR, US; <sup>2</sup>Department of Orthopedic Surgery; University of Arkansas for Medical Sciences, Little Rock, AR, US; <sup>3</sup>Center for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences Little Rock, AR, US; <sup>4</sup>Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, US.

**\*Corresponding author:** Jesús Delgado-Calle, Ph.D., Department of Physiology and Cell Biology, University of Arkansas for Medical Sciences, 4301 W. Markham St. Little Rock, AR 72205, E-mail: [jdelgadocalle@uams.edu](mailto:jdelgadocalle@uams.edu), Office: +1-501-686-7668; ORCID: 0000-0002-2083-2774.

**Funding:** This work was supported by the National Institutes of Health (NIH) R01CA209882 (J.D.C.), R37CA251763 (J.D.C.), R01CA241677 (J.D.C.), P20GM125503 (J.D.C.), and the UAMS Winthrop P. Rockefeller Cancer Institute Seeds of Science Award and Voucher Program (J.D.C.).

**Disclosure of Conflicts of Interest:** The author has declared that no conflict of interest exists.

The development of proteasome inhibitors (PIs) has significantly enhanced treatment responses and survival rates in patients with multiple myeloma (MM),<sup>1,2</sup> a hematological cancer characterized by the growth of malignant plasma cells in the bone marrow. Despite the high initial response rates to PIs, myeloma patients often experience relapses due to the development of drug resistance, preventing these therapies from achieving sustained or complete remission.

The precise cellular and molecular mechanisms underlying PI chemoresistance in MM are not fully understood. While myeloma relapse and resistance to PIs can be linked to genetic mutations in proteasomal components or drug efflux pumps, these events are relatively rare in patients.<sup>3</sup> Growing evidence suggests that non-mutational processes, including changes in the expression of genes related to survival signaling pathways, may play a significant role in PI chemoresistance.<sup>4</sup>

The balance within sphingolipid metabolism plays a crucial role in regulating cell survival by modulating pro-apoptotic molecules like ceramide and prosurvival factors like sphingosine-1-phosphate.<sup>5</sup> Disruption of this balance has been shown to promote cancer cell survival, thereby contributing to chemotherapy resistance by inhibiting cell death pathways. In this issue of *Haematologica*, Bishop et al. identified acid ceramidase, encoded by the gene *ASHA1*, an enzyme that catalyzes the hydrolysis of ceramide into sphingosine and fatty acids, as a key driver of PI resistance in MM.<sup>6</sup>

Utilizing RNA sequencing data from CD138<sup>+</sup> cells isolated from MM patients, the authors demonstrate that genes involved in sphingolipid metabolism are more highly expressed in refractory/relapsed patients compared to newly diagnosed individuals, correlating with worse survival outcomes. Among these genes, *ASA1* was significantly upregulated in the relapsed patients, and high *ASA1* expression was associated with increased levels of the anti-apoptotic

genes MCL1 and BCL2. Through elegant mechanistic studies, the team identified ASAH1 activates PP2A phosphatase activity, which in turn phosphorylates MCL1 and BCL2, thereby enhancing their anti-apoptotic effects.

While MCL1 and BCL2 have been previously linked to MM cell survival, pharmacological targeting of these anti-apoptotic molecules remains challenging.<sup>7</sup> The team built on their discoveries to explore the efficacy of targeting the ASAH1-PP2A anti-apoptotic signaling axis. They utilized Ceranib-2, a potent ceramidase inhibitor, to treat PI-resistant MM cell lines in mouse models, observing significant reductions in tumor burden. These results mirrored those obtained with genetic knockdown of ASAH1 in MM cells. To further explore the clinical relevance of their findings, the investigators utilized a platform called “Ex Vivo Mathematical Myeloma Advisor” (EMMA), created to advance clinical-informed decisions, research, and preclinical compound testing called in primary samples from MM patients.<sup>8</sup> Remarkably, the addition of Ceranib-2 improved responses to PI and resensitized cells from relapse MM patients to PI treatment.

This work has both basic/translational and clinical implications for the treatment of MM. First, it identifies a new mechanism of PI chemoresistance in relapsed/refractory MM patients. Second, it provides compelling evidence that ceramide metabolism enhances survival pathways and contributes to chemotherapy resistance, with the data providing rationale for clinical testing of Ceranib-2 and PI combination therapy in MM patients with relapsed/refractory disease. These exciting discoveries also raise several clinically relevant questions for translating these findings into clinical practice. For instance, what is the optimal combination of sphingolipid-targeting agents with other therapies? Can biomarkers of ceramide metabolism be identified for patient stratification? What are the efficacy and safety profiles of Ceranib-2 and similar agents in

combination with PIs? Ultimately, the studies by Bishop *et al.* deepen our understanding of the non-mutational molecular mechanisms of PI chemoresistance in MM and also provide a rationale for clinical trials exploring combination treatment that include sphingolipid-targeting agents novel to improve clinical outcomes for relapsed and refractory MM patients.

## References

1. Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. *Nat Rev Clin Oncol.* 2017;14(7):417-433.
2. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. *Am J Hematol.* 2020;95(5):548-567.
3. Barrio S, Stühmer T, Da-Viá M, et al. Spectrum and functional validation of PSMB5 mutations in multiple myeloma. *Leukemia.* 2019;33(2):447-456.
4. Guerrero-Garcia TA, Gandolfi S, Laubach JP, et al. The power of proteasome inhibition in multiple myeloma. *Expert Rev Proteomics.* 2018;15(12):1033-1052.
5. Ryland LK, Fox TE, Liu X, Loughran TP, Kester M. Dysregulation of sphingolipid metabolism in cancer. *Cancer Biol Ther.* 2011;11(2):138-149.
6. Bishop RT, Li T, Sudalagunta P, et al. Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed/refractory multiple myeloma. *Haematologica.* xxx
7. Gong JN, Khong T, Segal D, et al. Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. *Blood.* 2016;128(14):1834-1844.
8. Silva A, Silva MC, Sudalagunta P, et al. An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma. *Cancer Res.* 2017;77(12):3336-3351.